At a glance
- Originator Triangle Pharmaceuticals
- Class Antipsoriatics
- Mechanism of Action DNA synthesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 09 Sep 1999 No-Development-Reported for Psoriasis in USA (Topical)
- 20 Feb 1997 Preclinical development for Psoriasis in USA (Topical)